Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CHL006
MIFTS: 38

Childhood Oligodendroglioma

Categories: Cancer diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Childhood Oligodendroglioma

About this section

MalaCards integrated aliases for Childhood Oligodendroglioma:

Name: Childhood Oligodendroglioma 12 15
Oligodendroglioma, Childhood 74
Pediatric Oligodendroglioma 12

Classifications:

MalaCards categories:
Global: Cancer diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3183
MeSH 45 D009837
NCIt 51 C4045
UMLS 74 C0280475
Sources

Summaries for Childhood Oligodendroglioma

About this section
MalaCards based summary : Childhood Oligodendroglioma, also known as oligodendroglioma, childhood, is related to oligodendroglioma and cerebellar astrocytoma, and has symptoms including seizures and headache. An important gene associated with Childhood Oligodendroglioma is PLPP3 (Phospholipid Phosphatase 3), and among its related pathways/superpathways are Neuroscience and Neural Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Carmustine and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and spinal cord, and related phenotypes are homeostasis/metabolism and skeleton

Sources

Related Diseases for Childhood Oligodendroglioma

About this section

Diseases related to Childhood Oligodendroglioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 77)
# Related Disease Score Top Affiliating Genes
1 oligodendroglioma 29.3 GFAP IDH1 OLIG2 SYP TP73
2 cerebellar astrocytoma 10.4 IDH1 KIAA1549
3 pilocytic astrocytoma of cerebellum 10.4 IDH1 KIAA1549
4 mixed glioma 10.3 GFAP IDH1
5 glioma susceptibility 1 10.3 GFAP IDH1
6 spinal cord astrocytoma 10.3 GFAP IDH1
7 inflammatory mfh 10.3 GFAP MDM2
8 periosteal chondrosarcoma 10.2 IDH1 MDM2
9 desmoplastic infantile ganglioglioma 10.2 GFAP SYP
10 lung combined type small cell carcinoma 10.2 GFAP SYP
11 fibrillary astrocytoma 10.2 GFAP IDH1 KIAA1549
12 cellular ependymoma 10.2 GFAP SYP
13 pilocytic astrocytoma 10.2 GFAP IDH1 KIAA1549
14 chordoid meningioma 10.2 GFAP SYP
15 central nervous system primitive neuroectodermal neoplasm 10.2 GFAP SYP
16 clear cell ependymoma 10.2 GFAP SYP
17 chiari malformation 10.2 GFAP SYP
18 periosteal osteogenic sarcoma 10.2 IDH1 MDM2
19 cerebral neuroblastoma 10.2 GFAP SYP
20 subependymal glioma 10.2 GFAP SYP
21 astroblastoma 10.2 GFAP SYP
22 pineal gland cancer 10.2 GFAP SYP
23 melanotic neuroectodermal tumor 10.2 GFAP SYP
24 obstructive hydrocephalus 10.2 GFAP SYP
25 partial motor epilepsy 10.2 RBFOX3 SYP
26 gangliocytoma 10.2 RBFOX3 SYP
27 medulloepithelioma 10.2 GFAP SYP
28 pineocytoma 10.2 GFAP SYP
29 cauda equina neoplasm 10.2 RBFOX3 SYP
30 subependymoma 10.2 GFAP SYP
31 sella turcica neoplasm 10.1 RBFOX3 SYP
32 pineoblastoma 10.1 GFAP SYP
33 von economo's disease 10.1 GFAP SNCA
34 tuberculum sellae meningioma 10.1 RBFOX3 SYP
35 papilloma of choroid plexus 10.1 GFAP SYP
36 central neurocytoma 10.1 GFAP SYP
37 gliomatosis cerebri 10.1 GFAP IDH1 MDM2
38 nodular ganglioneuroblastoma 10.1 MDM2 SYP
39 binswanger's disease 10.1 GFAP SYP
40 cystic teratoma 10.1 GFAP SYP
41 extraventricular neurocytoma 10.1 GFAP IDH1 SYP
42 dysembryoplastic neuroepithelial tumor 10.1 GFAP IDH1 SYP
43 pilomyxoid astrocytoma 10.1 GFAP KIAA1549 SYP
44 angiocentric glioma 10.1 GFAP IDH1 SYP
45 ependymoma 10.1 GFAP SYP TP73
46 pleomorphic xanthoastrocytoma 10.1 GFAP IDH1 SYP
47 subependymal giant cell astrocytoma 10.1 GFAP SYP
48 cerebellopontine angle tumor 10.1 GFAP IDH1 SYP
49 peripheral osteosarcoma 10.1 IDH1 MDM2
50 central nervous system benign neoplasm 10.0 GFAP SYP

Graphical network of the top 20 diseases related to Childhood Oligodendroglioma:



Diseases related to Childhood Oligodendroglioma
Sources

Symptoms & Phenotypes for Childhood Oligodendroglioma

About this section

UMLS symptoms related to Childhood Oligodendroglioma:


seizures, headache

MGI Mouse Phenotypes related to Childhood Oligodendroglioma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.61 GFAP IDH1 KIAA1549 MDM2 PLPP3 SNCA
2 skeleton MP:0005390 9.1 IDH1 MDM2 OLIG2 SNCA SPON1 TP73
Sources

Drugs & Therapeutics for Childhood Oligodendroglioma

About this section

Drugs for Childhood Oligodendroglioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 380)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carmustine Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 154-93-8 2578
2
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
3
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
4
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
5
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
6
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
7
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
8
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 85622-93-1 5394
9
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1 52-24-4 5453
10
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
11
Methotrexate Approved Phase 3,Phase 2,Not Applicable 1959-05-2, 59-05-2 126941
12
Lomustine Approved, Investigational Phase 3,Phase 2,Phase 1 13010-47-4 3950
13
Procarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 671-16-9 4915
14
Ondansetron Approved Phase 3 99614-02-5 4595
15
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
16
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
17
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 1177-87-3
18
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
19
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
20
Histamine Approved, Investigational Phase 3,Phase 2 51-45-6 774
21
Cyproheptadine Approved Phase 3,Phase 2 129-03-3 2913
22
Dopamine Approved Phase 3,Early Phase 1,Not Applicable 62-31-7, 51-61-6 681
23
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
24
Isotretinoin Approved Phase 3,Phase 1 4759-48-2 5282379 5538
25
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
26
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1 302-79-4 444795 5538
27 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
28 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
31 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
32 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
34 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
35 Vitamin B9 Phase 3,Phase 2,Phase 1,Not Applicable
36 Folate Phase 3,Phase 2,Phase 1,Not Applicable
37 Folic Acid Antagonists Phase 3,Phase 2,Not Applicable
38 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
39 Dermatologic Agents Phase 3,Phase 1,Phase 2,Not Applicable
40 Etoposide phosphate Phase 3,Phase 2,Phase 1,Not Applicable
41 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
42 Vitamin B Complex Phase 3,Phase 2,Phase 1,Not Applicable
43 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
44 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
45 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
46 Keratolytic Agents Phase 3,Phase 1,Phase 2
47 Gastrointestinal Agents Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
48 Antiemetics Phase 3,Phase 1
49 Emetics Phase 3,Phase 1
50 BB 1101 Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 370)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
2 Carboplatin Plus Vincristine in Treating Children and Adolescents With Low Grade Glioma Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
3 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
4 Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
5 Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
6 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
7 Radiation Therapy or Temozolomide in Treating Patients With Gliomas Completed NCT00182819 Phase 3 temozolomide
8 Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
9 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
10 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
11 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
12 Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma Recruiting NCT01649830 Phase 3 Temozolomide
13 Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
14 Phase III Trial of Anaplastic Glioma Without 1p/19q LOH Active, not recruiting NCT00626990 Phase 3 temozolomide
15 Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma Active, not recruiting NCT00978458 Phase 3 temozolomide
16 Treatment Strategy for Low-grade Gliomas Terminated NCT00897377 Phase 3 Temozolomide
17 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
18 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
19 Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
20 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
21 A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma Unknown status NCT00683761 Phase 1, Phase 2 131I-TM601
22 Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma Unknown status NCT00004204 Phase 2 temozolomide
23 Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas Unknown status NCT01024907 Phase 1, Phase 2
24 Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma Unknown status NCT00360945 Phase 2 cisplatin;temozolomide
25 Radiation Therapy in Treating Young Patients With Gliomas Unknown status NCT00238264 Phase 2
26 Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
27 Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme Unknown status NCT00892177 Phase 2 dasatinib
28 A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
29 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
30 Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial Completed NCT01847235 Phase 2 Temozolomide
31 Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00362570 Phase 2 Temozolomide
32 Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma Completed NCT00003101 Phase 2 busulfan;lomustine;procarbazine hydrochloride;thiotepa;vincristine sulfate
33 Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma Completed NCT00400816 Phase 2 temozolomide
34 Temozolomide in Treating Patients With Anaplastic Oligodendroglioma Completed NCT00003465 Phase 2 temozolomide
35 Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas Completed NCT00033280 Phase 2 temozolomide
36 Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma Completed NCT00004024 Phase 2
37 Topotecan in Treating Patients With Recurrent Brain Tumors Completed NCT00003372 Phase 2 topotecan hydrochloride
38 Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma Completed NCT01663012 Phase 2 Etirinotecan pegol
39 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
40 Prolonged Daily Temozolomide for Low-Grade Glioma Completed NCT00165360 Phase 2 Temozolomide
41 Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) Completed NCT00615927 Phase 2 Imatinib Mesylate & Hydroxyurea
42 Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors Completed NCT00667394 Phase 2 MLN-518 (Tandutinib)
43 Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors Completed NCT00003304 Phase 2 temozolomide
44 Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors Completed NCT00012038 Phase 1, Phase 2 irofulven
45 Procarbazine in Treating Patients With Recurrent Brain Tumor Completed NCT00004004 Phase 1, Phase 2 procarbazine hydrochloride
46 Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma Completed NCT00575887 Phase 2 Temozolomide
47 The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601) Completed NCT00392171 Phase 2 Temozolomide
48 Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors Completed NCT00003731 Phase 2 temozolomide
49 Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms Completed NCT00004688 Phase 2 carmustine;mercaptopurine;streptozocin
50 A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis Completed NCT00565721 Phase 2 Fluciclatide Injection - (AH111585 (F18))

Search NIH Clinical Center for Childhood Oligodendroglioma

Sources

Genetic Tests for Childhood Oligodendroglioma

About this section
Sources

Anatomical Context for Childhood Oligodendroglioma

About this section

MalaCards organs/tissues related to Childhood Oligodendroglioma:

42
Brain, Bone, Spinal Cord, Bone Marrow, T Cells, Liver, Kidney
Sources

Publications for Childhood Oligodendroglioma

About this section

Articles related to Childhood Oligodendroglioma:

# Title Authors Year
1
Outcomes and Prognostic Factors in Pediatric Oligodendroglioma: A Population-Based Study. ( 29131101 )
2018
2
Predictors of clinical outcome in pediatric oligodendroglioma: meta-analysis of individual patient data and multiple imputation. ( 29192869 )
2018
3
Conventional and advanced (DTI/SWI) neuroimaging findings in pediatric oligodendroglioma. ( 25813856 )
2015
Sources

Variations for Childhood Oligodendroglioma

About this section
Sources

Expression for Childhood Oligodendroglioma

About this section
Search GEO for disease gene expression data for Childhood Oligodendroglioma.
Sources

Pathways for Childhood Oligodendroglioma

About this section

Pathways related to Childhood Oligodendroglioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Neuroscience 4
11.79 GFAP RBFOX3 SNCA SYP
2
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 66
10.7 GFAP OLIG2 SYP
3
TP53 Network 1
Show member pathways
 10.5 MDM2 TP73
Sources

GO Terms for Childhood Oligodendroglioma

About this section

Biological processes related to Childhood Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 synaptic vesicle endocytosis GO:0048488 9.37 SNCA SYP
2 response to steroid hormone GO:0048545 9.32 IDH1 MDM2
3 regulation of long-term neuronal synaptic plasticity GO:0048169 9.26 SNCA SYP
4 regulation of neuronal synaptic plasticity GO:0048168 9.16 SNCA SYP
5 positive regulation of oligodendrocyte differentiation GO:0048714 8.96 OLIG2 TP73
6 response to magnesium ion GO:0032026 8.62 MDM2 SNCA

Molecular functions related to Childhood Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.1 GFAP IDH1 MDM2 SNCA SYP TP73
2 beta-tubulin binding GO:0048487 8.96 PDCD5 SNCA
Sources

Sources for Childhood Oligodendroglioma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....